Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
47.12
87
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Beijing Wantai Biological Pharmacy Enterprise Co Ltd stock under the Base Case scenario is 63.19 CNY. Compared to the current market price of 73.17 CNY, Beijing Wantai Biological Pharmacy Enterprise Co Ltd is Overvalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Beijing Wantai Biological Pharmacy Enterprise Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has emerged as a key player in the Chinese biopharmaceutical landscape, combining innovation with a commitment to improving healthcare outcomes. Founded in 1990, the company specializes in the research, development, manufacturing, and sale of a wide range of vaccines, diagnostic reagents, and biologic drugs. As one of the forefront companies in China's biotech sector, Wantai has leveraged its technological expertise to create products that address significant public health needs, such as viral infections and autoimmune diseases. With a robust pipeline and strong government support, the company positions itself as a critical contributor...
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has emerged as a key player in the Chinese biopharmaceutical landscape, combining innovation with a commitment to improving healthcare outcomes. Founded in 1990, the company specializes in the research, development, manufacturing, and sale of a wide range of vaccines, diagnostic reagents, and biologic drugs. As one of the forefront companies in China's biotech sector, Wantai has leveraged its technological expertise to create products that address significant public health needs, such as viral infections and autoimmune diseases. With a robust pipeline and strong government support, the company positions itself as a critical contributor to the nation's healthcare ecosystem while aligning with global trends in biopharmaceutical development.
For investors, Wantai represents an attractive opportunity, particularly as the demand for effective vaccines and diagnostics continues to surge worldwide. The company's recent IPO and strategic partnerships have bolstered its financial standing, providing a solid foundation for future growth. With an expanding portfolio that includes COVID-19 vaccines and innovative therapeutics, Wantai is poised to capitalize on the growing emphasis on preventative medicine and public health. Moreover, the company's commitment to quality and extensive research capabilities create a sustainable competitive advantage that could yield promising returns for investors navigating the evolving biotechnology market.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a prominent biopharmaceutical company based in China. The company engages in various segments within the pharmaceutical and biotechnology industries. Here are the core business segments:
-
Biological Products: This segment focuses on the development and manufacturing of vaccines and other biological products. The company is known for its recombinant vaccine production, which addresses various infectious diseases.
-
Diagnostic Reagents: Wantai Biological develops and manufactures diagnostic kits and reagents used for disease diagnosis and monitoring. This includes products for infectious diseases, and other medical diagnostics, enhancing the capabilities of healthcare providers.
-
Traditional Chinese Medicine: This segment includes the development of traditional Chinese medicinal products, which often combine modern pharmaceutical techniques with traditional herbal remedies.
-
Medical Devices: The company may also be involved in the production and distribution of medical devices, focusing on innovative tools that improve healthcare monitoring and treatment.
-
Research and Development: Wantai Biological invests significantly in R&D to advance their technological capabilities and product offerings, focusing on innovation to meet emerging healthcare needs.
-
Export and International Collaboration: The company engages in international business, which may include exporting products to other countries and forming partnerships for development and distribution.
These segments illustrate Wantai Biological's commitment to improving public health through innovative biopharmaceutical solutions, capturing a significant market share in both domestic and international markets.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has several unique competitive advantages that differentiate it from its rivals in the biopharmaceutical industry:
-
Strong R&D Capabilities: Wantai invests significantly in research and development, which allows it to innovate and develop new products. They have a robust pipeline of vaccines and diagnostic products that can meet market demands.
-
Diverse Product Portfolio: The company has a wide range of products, including vaccines, diagnostic reagents, and blood products. This diversification helps mitigate risk and enhances its market presence across different segments.
-
Regulatory Approvals: Beijing Wantai has navigated the regulatory landscape effectively to achieve approvals for its products both domestically and internationally, providing a competitive edge in product commercialization.
-
Strategic Partnerships: Collaborations with research institutions and other pharmaceutical companies boost their capabilities in innovation and market reach, allowing them to leverage expertise and resources.
-
Strong Market Presence in China: As a prominent pharmaceutical company in China, Wantai benefits from a large domestic market, which is continually expanding, especially within the healthcare sector.
-
Focus on Public Health: The company’s emphasis on vaccines and diagnostics aligns with growing global health concerns, allowing them to position themselves strategically in crucial sectors.
-
Experienced Management Team: The leadership at Beijing Wantai brings extensive industry experience and strategic vision, enabling effective decision-making and adaptability in changing market conditions.
-
Cost-effective Production: They leverage economies of scale in production, which can lead to lower costs and improved margins compared to smaller competitors.
-
Brand Reputation: A well-established brand associated with quality and reliability in vaccines and diagnostics enhances customer trust, leading to competitive advantages in customer acquisition and retention.
-
Global Expansion Strategies: The company’s efforts to penetrate international markets allow them to diversify revenue streams and reduce reliance on any single market.
By leveraging these competitive advantages, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. can position itself effectively against its rivals in the biopharmaceutical industry.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. faces several risks and challenges that could impact its operations and growth in the near future, including:
-
Regulatory Environment: The pharmaceutical industry is highly regulated. Changes in government policies, approval processes for new drugs, and compliance requirements could pose significant challenges.
-
Market Competition: The biotechnology and pharmaceutical sectors are highly competitive. New entrants and existing players developing innovative therapies could threaten Wantai's market share.
-
Research and Development (R&D): Heavy investment in R&D is essential for producing new products. The uncertainty surrounding the success of these investments could lead to financial strain if expected outcomes are not realized.
-
Supply Chain Disruptions: Global supply chain issues, exacerbated by geopolitical tensions, pandemics, or other external factors, could affect the availability of raw materials and components necessary for production.
-
Intellectual Property Risks: The company faces risks regarding patent infringements or challenges to its intellectual property, which could impede its ability to commercialize products.
-
Pricing Pressure and Reimbursement Challenges: Pricing regulations and reimbursement issues by public health systems can impact the profitability of new drugs.
-
Economic Conditions: Macroeconomic factors, such as economic downturns or fluctuations in currency exchange rates, can affect funding opportunities and consumer demand.
-
Public Perception and Trust: Trust in pharmaceutical companies can be fragile. Any issues related to ethics, safety, or efficacy of products can damage the company's reputation and sales.
-
Technological Advancements: Staying abreast of rapid technological changes and innovations is crucial. Failure to adapt to new technologies or trends in the industry can hinder competitive positioning.
-
Global Expansion Risks: For companies looking to expand internationally, such as Wantai, challenges include understanding and navigating diverse regulatory landscapes, cultural differences, and local market dynamics.
-
Labor and Talent Acquisition: Attracting and retaining skilled personnel in R&D and production is crucial for innovation. A competitive job market can pose challenges in this regard.
-
Product Liability Risks: As with any pharmaceutical company, there is the risk of lawsuits related to product safety or efficacy, which can lead to financial losses and reputational harm.
Overall, while Beijing Wantai Biological Pharmacy has opportunities for growth, these challenges necessitate strategic planning and robust risk management practices.
Revenue & Expenses Breakdown
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Balance Sheet Decomposition
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Current Assets | 9.2B |
Cash & Short-Term Investments | 5.6B |
Receivables | 2.7B |
Other Current Assets | 898.9m |
Non-Current Assets | 5.8B |
Long-Term Investments | 1.3B |
PP&E | 3.3B |
Intangibles | 685.6m |
Other Non-Current Assets | 496.5m |
Current Liabilities | 2.1B |
Accounts Payable | 406.8m |
Accrued Liabilities | 175.1m |
Short-Term Debt | 114.6m |
Other Current Liabilities | 1.4B |
Non-Current Liabilities | 360m |
Long-Term Debt | 141.3m |
Other Non-Current Liabilities | 218.8m |
Earnings Waterfall
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Revenue
|
2.5B
CNY
|
Cost of Revenue
|
-771.7m
CNY
|
Gross Profit
|
1.7B
CNY
|
Operating Expenses
|
-2.3B
CNY
|
Operating Income
|
-544.9m
CNY
|
Other Expenses
|
250.8m
CNY
|
Net Income
|
-294m
CNY
|
Free Cash Flow Analysis
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
According to Wall Street analysts, the average 1-year price target for Beijing Wantai Biological Pharmacy Enterprise Co Ltd is 62.63 CNY with a low forecast of 48.99 CNY and a high forecast of 78.02 CNY.
Dividends
Current shareholder yield for Beijing Wantai Biological Pharmacy Enterprise Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and equipment, and vaccines. The company is headquartered in Beijing, Beijing and currently employs 3,103 full-time employees. The company went IPO on 2020-04-29. The firm produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The firm is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
Contact
IPO
Employees
Officers
The intrinsic value of one Beijing Wantai Biological Pharmacy Enterprise Co Ltd stock under the Base Case scenario is 63.19 CNY.
Compared to the current market price of 73.17 CNY, Beijing Wantai Biological Pharmacy Enterprise Co Ltd is Overvalued by 14%.